UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up
NCT ID: NCT06232538
Last Updated: 2024-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1 participants
OBSERVATIONAL
2024-01-01
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
NCT05237193
Hepatobiliary Tumors Tissue Samples Acquisition
NCT04445532
A Single-center, Prospective Cohort Study on the Differentiation of Benign and Malignant Bile Duct Stenosis Based on Bile and Peripheral Blood cfDNA Methylation Profiles
NCT06115655
Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer
NCT01034865
Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma
NCT05327907
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
gallbladder cancer
The level of CNV
The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
benign gallbladder diseases
The level of CNV
The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The level of CNV
The extracted DNA from bile will be analyzed by UCAD to determine the level of CNV. And the patient will be followed more than 1 year.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patients aged \>= 18 years.
* Participants signed informed consent form.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Ruijin Hospital
OTHER
Changhai Hospital
OTHER
Shanghai Changzheng Hospital
OTHER
Eastern Hepatobiliary Surgery Hospital
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Jiangsu Provincial People's Hospital
OTHER
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
First Affiliated Hospital of Zhejiang University
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Second Hospital of Jilin University
OTHER
West China Hospital
OTHER
Southwest Hospital, China
OTHER
Affiliated Hospital of North Sichuan Medical College
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xinhua Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife. 2018 Sep 4;7:e37294. doi: 10.7554/eLife.37294.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XH-24-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.